AVIR Atea Pharmaceuticals Inc
Company Analysis
Latest News
🔴 Atea Pharmaceuticals is trading 12.2% down today, lagging a weak biotech sector on no specific news
Atea Pharmaceuticals is trading at $4.23 (down 12.2%), notably underperforming a declining biotech group and mixed broader indices. • The move appears driven...
🔴 Atea Pharmaceuticals is trading 5.5% down today as it underperforms a rallying biotech sector
Atea Pharmaceuticals is trading 5.5% down at $4.55, underperforming a rallying biotech sector and a mixed broader market despite a lack of fresh...
Atea Pharmaceuticals advances AT-587, targeting first-ever Hepatitis E treatment
Atea Pharmaceuticals launched a first-in-human Phase 1 clinical trial for AT-587. This oral antiviral candidate targets the hepatitis E virus (HEV). No...
🔴 Atea Pharmaceuticals is trading 5.4% down today amid broader biotech weakness and profit-taking
Atea Pharmaceuticals is trading at $4.72 (-5.41%) amid broader biotech sector weakness and profit-taking following a strong rally. • The decline aligns with a...
🔴 Atea Pharmaceuticals Inc is trading 5.01% down in after-hours
AVIR is trading at $4.74, down 5.01% in after-hours.
🔴 AVIR trading 9.4% down despite Phase 3 enrollment completion
AVIR is trading at $4.06 (9.4% down) in pre-market. The company announced today the completion of patient enrollment in its Phase 3 C-FORWARD trial for...
Atea Pharmaceuticals Shareholders Approve All Proposals at 2026 Annual Meeting
Atea Pharmaceuticals announced the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. All proposals presented were approved by the...